AMH stands for Anti-Mullerian Hormone. In women, it is produced by small follicles in the ovaries, so the blood level gives a rough idea of how many eggs remain available in the ovarian pool. That is why AMH is commonly used as a marker of ovarian reserve.

The key point is that AMH reflects egg quantity, not egg quality. A woman can have a low AMH and still conceive, especially if she ovulates and has good-quality eggs for her age. AMH is useful, but it should never be treated as a standalone fertility score.

AMH helps estimate how much reproductive time may remain, which can be useful when deciding whether to try sooner, wait, or consider egg freezing. It is also widely used before IVF because it helps predict how the ovaries may respond to stimulation medicines.

Doctors may also use AMH as one clue when discussing early menopause risk or broader fertility planning. But AMH is not a fertility crystal ball. It cannot predict exactly when pregnancy will happen or whether someone will conceive naturally this month.

AMH must always be read in the context of age. Broad guideposts often used are: around age 25, above 2.5 ng/ml; age 30, about 1.5 to 3; age 35, about 0.7 to 2; age 40, about 0.3 to 1; and by 45, often below 0.3.

These are not hard pass-fail cutoffs because lab methods differ and individual biology varies. A low AMH does not mean zero chance of pregnancy. It usually means fewer remaining eggs and, over time, a lower probability compared with someone of the same age who has a higher reserve.

AMH testing is reasonable if you are thinking about pregnancy after age 30, want more clarity for family planning, or are preparing for IUI or IVF. It is also useful after chemotherapy, with suspected premature ovarian insufficiency, or when periods are changing unexpectedly.

Some people test simply because they want a realistic timeline rather than reassurance. That is a fair reason, especially if marriage, career timing, or partner planning may delay pregnancy. The result is most useful when it changes a decision.

AMH does not directly measure egg quality, and quality is often more important than quantity for natural conception and miscarriage risk. It also does not tell you your exact chance of getting pregnant this month or exactly how long it will take.

It cannot precisely predict the age of menopause, and it does not fully predict how your ovaries will respond to every fertility drug protocol. AMH is one data point, not the whole fertility story.

In India, AMH is usually paired with Day 2 to 3 FSH, LH, and estradiol, which often cost about Rs 600 to Rs 1,500 depending on the lab and city. Thyroid testing and prolactin are commonly added because thyroid disorders or high prolactin can affect cycles and ovulation.

Antral follicle count through transvaginal ultrasound is another key companion test and often costs around Rs 600 to Rs 1,500. A full ovarian reserve workup commonly lands in the Rs 2,000 to Rs 5,000 range, depending on whether scans and extra hormone tests are bundled.

AMH pricing in India usually falls in a mid-range rather than being a premium-only test. Typical quotes are about Rs 1,500 to Rs 2,500 at Dr Lal PathLabs, Rs 1,500 to Rs 2,200 at Metropolis, Rs 1,200 to Rs 2,000 at Thyrocare, and Rs 1,500 to Rs 2,500 at SRL.

Home collection may add roughly Rs 200 to Rs 500. Prices vary by city, discounts, and packages, so it is worth comparing before booking. If you are already doing ultrasound and hormone testing, a bundled fertility panel may make more sense than ordering AMH alone.

The first step is to review the result with a fertility specialist, ideally an ISAR-affiliated doctor, not to panic over the number itself. Low AMH may mean less time or a lower egg reserve, but it does not prove infertility. Age, ovulation status, ultrasound findings, and partner semen factors all matter.

If you are younger and not ready for pregnancy, egg freezing may be worth discussing. If you do want children, trying sooner may be more sensible than waiting. In IVF, doctors can adjust stimulation protocols, and emotional support matters because AMH results often trigger disproportionate anxiety.

A high AMH can be seen in people with polycystic ovary syndrome, and very high values, often above 4 ng/ml, make doctors think about PCOS first. High AMH is not automatically a sign of excellent fertility because irregular ovulation can still make conception difficult.

In IVF, high AMH can mean a stronger response to stimulation and a higher risk of OHSS, so clinics often use modified protocols. The right next step is to assess symptoms, cycle pattern, ultrasound findings, weight, insulin resistance, and the broader PCOS picture rather than celebrating the number.

AMH is best interpreted by a fertility specialist, preferably an ISAR member, because the number can be misleading when seen alone. A general practitioner may explain the result at a basic level, but fertility decisions should not be made from AMH in isolation.

The specialist will combine age, menstrual history, ultrasound antral follicle count, prior pregnancies, miscarriage history, treatment goals, and partner factors. That full picture is what makes the result clinically useful.